Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial

Antonio Jose Inda-Filho, Adriano Caixeta, Marcia Manggini, Nestor Schor, Antonio Jose Inda-Filho, Adriano Caixeta, Marcia Manggini, Nestor Schor

Abstract

Background: N-acetylcysteine (NAC) or sodium bicarbonate (NaHCO3), singly or combined, inconsistently prevent patients exposed to radiographic contrast media from developing contrast-induced acute kidney injury (CI-AKI).

Objective: We asked whether intravenous isotonic saline and either NaHCO3 in 5% dextrose or else a high dose of NAC in 5% dextrose prevent CI-AKI in outpatients exposed to high-osmolal iodinated contrast medium more than does saline alone.

Methods: This completed prospective, parallel, superiority, open-label, controlled, computer-randomized, single-center, Brazilian trial (NCT01612013) hydrated 500 adult outpatients (214 at high risk of developing CI-AKI) exposed to ioxitalamate during elective coronary angiography and ventriculography. From 1 hour before through 6 hours after exposure, 126 patients (group 1) received a high dose of NAC and saline, 125 (group 2) received NaHCO3 and saline, 124 (group 3) received both treatments, and 125 (group 4) received only saline.

Results: Groups were similar with respect to age, gender, weight, pre-existing renal dysfunction, hypertension, medication, and baseline serum creatinine and serum cystatin C, but diabetes mellitus was significantly less prevalent in group 1. CI-AKI incidence 72 hours after exposure to contrast medium was 51.4% (257/500), measured as serum creatinine > (baseline+0.3 mg/dL) and/or serum cystatin C > (1.1 · baseline), and 7.6% (38/500), measured as both serum creatinine and serum cystatin C > (baseline+0.3 mg/dL) or > (1.25 · baseline). CI-AKI incidence measured less sensitively was similar among groups. Measured more sensitively, incidence in group 1 was significantly (p<0.05) lower than in groups 2 and 3 but not group 4; adjustment for confounding by infused volume equalized incidence in groups 1 and 3.

Conclusion: We found no evidence that intravenous isotonic saline and either NaHCO3 or else a high dose of NAC prevent CI-AKI in outpatients exposed to high osmolal iodinated contrast medium more than does saline alone.

Trial registration: ClinicalTrials.gov NCT01612013.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow of 500 outpatients through…
Figure 1. Flow of 500 outpatients through a parallel trial of four treatments for preventing CI-AKI.
Practice of the trial design. Abbreviations: CI-AKI (contrast-induced acute kidney injury), IV (intravenous), NAC (N-acetylcysteine), NaHCO3 (sodium bicarbonate).
Figure 2. Change in serum creatinine and…
Figure 2. Change in serum creatinine and cystatin C levels of 500 outpatients exposed to ioxitalamate.
Mean of serum creatinine (panel A) and serum cystatin C (panel B) concentrations before (baseline) and after administration of ioxitalamate, according to treatment group. Treatments: NAC (N-acetylcysteine plus saline; group 1), NaHCO3 (sodium bicarbonate plus saline; group 2), NAC+NaHCO3 (N-acetylcysteine plus sodium bicarbonate plus saline; group 3), saline (group 4). Means among the treatment groups did not differ significantly. Error bars indicate 1 standard deviation about the mean.

References

    1. MacCullough PA (2008) Contrast-induced acute kidney injury. J Am Coll Cardiol 51(15): 1419–1428.
    1. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, et al. (1989) Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320(3): 143–149.
    1. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, et al. (1999) A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. Prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol 33(2): 403–411.
    1. Solomon R, Werner C, Mann D, D’Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331: 1416–1420.
    1. Brown JR, Block CA, Malenka DJ, O'Connor GT, Schoolwerth AC, et al. (2009) Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Intverv 2(11): 1116–1124.
    1. Mehran R, Caixeta A (2010) N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question. Rev Esp Cardiol 63(1): 9–11.
    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127(1): e6–e245 Available: Accessed: 2014 Aug 29..
    1. Nikolsky E, Mehran R (2003) Understanding the consequences of contrast-induced nephropathy. Rev Cardiovasc Med (suppl 5): S10–18.
    1. Barreto R (2007) Prevention of contrast-induced nephropathy: the rational use of sodium bicarbonate. Nephrol Nurs J 34(4): 417–421.
    1. McCullough PA, Sandberg KR (2003) Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med (suppl 5): S3–S9.
    1. Choudhury D (2010) Acute kidney injury: current perspectives. Postgrad Med 122(6): 29–40.
    1. Ellis HE, Cohan RH (2009) Prevention of contrast-induced nephropathy: an overview. Radiol Clin North Am 47(5): 801–811.
    1. Heng AE, Cellarier E, Aublet-Cuvelier B, Decalf V, Motreff P, et al. (2008) Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date? Clin Nephrol 70(6): 475–484.
    1. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, et al. (2010) Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 55(20): 2201–2209.
    1. Sun Z, Fu Q, Cao L, Jin W, Cheng L, et al. (2013) Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLOS One 8(1): e55124 Available: Accessed: 2014 Aug 29..
    1. Kwok CS, Pang CL, Yeong JK, Loke YK (2013) Measures used to treat contrast-induced nephropathy: overview of reviews. Br J Radiol 86(1021): 20120272.
    1. Droppa M, Desch S, Blase P, Eitel I, Fuernau G, et al. (2011) Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol 100(11): 1037–1043.
    1. Henry RJ, Cannon DC, Winkelman NJW (1974) Clinical chemistry: Principles and technics. 2nd ed. New York: Harper & Row.
    1. Finney H, Newman DJ, Gruber W, Merle P, Price CP (1997) Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 43(6): 1016 1022.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6): 461–470.
    1. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, et al. (2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51(3): 395–406.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Supplement 2: 69–88.
    1. Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, et al. (2012) Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clinical Chemistry 58(2): 458–464.
    1. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, et al. (2004) A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 148: 422–429.
    1. Carbonell N, Blasco M, Sanjuán R, Pérez-Sancho E, Sanchis J, et al. (2007) Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomized trial. Int J Cardiol 115: 57–62.
    1. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M (2003) Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol 58: 555–560.
    1. Poletti PA, Saudan P, Planton A, Mermillod B, Sautter AM, et al. (2007) IV N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. Am J Roentgenol 189: 687–692.
    1. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, et al. (2004) Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg 40: 1136–1141.
    1. Jaffery Z, Verma A, White CJ, Grant AG, Collins TJ, et al. (2012) A randomized trial of intravenous N-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv 6: 921–926.
    1. Adolph E, Holdt-Lehmann B, Chatterjee T, Paschka S, Prott A, et al. (2008) Renal Insufficiency Following Radiocontrast Exposure trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 19: 413–419.
    1. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, et al. (2008) Sodium bicarbonate versus saline for prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 52: 599–604.
    1. Schmidt P, Pang D, Nykamp D, Knowlton G, Jia H (2007) N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography. Ann Pharmacother 41: 46–50.
    1. Hafiz AM, Jan MF, Mori N, Shaikh F, Wallach J, et al.. (2012) Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of preventive strategies. Catheter Cardiovasc Interv 79(6): 929–937..
    1. Ueda H, Yamada T, Masuda M, Okuyama Y, Morita T, et al. (2011) Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing coronary procedures. Am J Cardiol 107(8): 1163–1167.
    1. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, et al. (2012) Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury – a systematic review and meta-analysis. Circ J 9: 2255–2265.
    1. Merten GB, Burgess WP, Gray LV, Holleman JH, Roush TS, et al. (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291: 2328–2334.
    1. Backer CS, Wragg A, Kumar S, De Palma R, Baker LR, et al. (2003) A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41: 2114–2118.
    1. Briguori C, Arioldi F, D'Andrea D, Bonizzoni E, Morici N, et al. (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115: 1211–1217.
    1. Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, et al. (2007) The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO study. J Am Coll Cardiol 49: 1283–1288.
    1. Leone A, De Catarina A, Sciahbasi A, Aurelio A, Basile E, et al. (2012) Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (Bicarbonato e N-acetil-cisteina nell'infaRto miocardico acuto) study. Euro Intervention 7: 839–847.
    1. Brown JR, Block CA, Malenka DJ, O'Connor GT, Schoolwerth AC, et al. (2009) Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv. 2(11): 1116–1124.
    1. Fishbane S (2008) N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 3: 281–287..
    1. Caulfield JL, Singh SP, Wishnok JS, Deen WM, Tannenbaum SR, et al. (1996) Bicarbonate Inhibits N-nitrosation in oxygenated nitric oxide solutions. J Biol Chem 271(42): 25859–25863.
    1. Herget-Rosenthal S, Marggraf G, Husing J, Göring F, Pietruck F, et al. (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int. 66: 1115–1122.
    1. Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, et al. (2010) Cystatin C and contrast-induced acute kidney injury. Circulation 2010 121: 2117–2122.
    1. Newhouse JH, Kho D, Rao QA, Starren J (2008) Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 191: 376–382.
    1. Chao CT (2013) Epidemiology, clinical features and diagnosis of contrast induced nephropathy: a brief review. General Med 1: 102.
    1. Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C (2003) Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 63(5): 1944–1947.
    1. McMahon GM, Waikar SS (2013) Biomarkers in nephrology: core curriculum 2013. Am J Kidney Dis 62(1): 165–178.
    1. Barret BJ, Carlisle EJ (1993) Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188: 171–178.
    1. Rudnick MR, Goldforbs S, Wexler L, Ludbrook PA, Murphy MJ, et al. (1995) Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 47: 254–261.
    1. Ad-hoc working group of ERBP, Fliser D, Laville M, Covic A, Fouque D, et al. (2012) A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: Part 1: Definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 27(12): 4263–4272.
    1. James M, Bouchard J, Ho J, Klarenbach S, LaFrance JP, et al. (2013) Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 5: 673–685.
    1. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, et al. (2004) N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 15(3): 761–769.
    1. Zagler A, Azadpour M, Mercado C, Hennekens CH (2006) N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 151(1): 140–145.
    1. ACT Investigators (2011) Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-Induced Nephropathy trial (ACT). Circulation 124(11): 1250–1259.
    1. Chertow GM, Palevsky PM, Greene T (2006) Studying the prevention of acute kidney injury: lessons from an 18th-century mathematician. Clin J Am Soc Nephrol 1(4): 1124–1127.
    1. Reddan D, Laville M, Garovic VD (2009) Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol 22(3): 333–351.
    1. Hollis S, Campbell F (1999) What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319: 670–674.
    1. Keirse MJNC, Hanssens M (2000) Control of error in randomised clinical trials. Eur J Obstet Gynecol Reprod Biol 92: 67–74.
    1. Schultz KF, Grimes DA (2002) Sample size slippages in randomised controlled trials: exclusions and the lost and wayward. Lancet 359: 781–785.
    1. Rubin DB (1987) Multiple imputation for nonresponse in surveys. New York: John Wiley and Sons.
    1. van Buuren S (2012) Flexible imputation of missing data. Boca Raton: CRC Press.
    1. Bellomo R, Ronco C, Kellum JA, Mehta RL (2004) Acute Dialysis Quality Initiative workgroup: acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs. The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8: R204–R212.
    1. McDonald RJ, McDonald JS, Bida JP, Carter RE, Fleming CJ, et al. (2013) Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 267(1): 106–118.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj